Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of the invention, an aqueous solution containing gold salts is mixed with soy or lentil plant material or a reactive extract thereof. In preferred embodiment methods of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with soy or lentil plant material or a reactive extract thereof. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a robust coating derived of the soy or lentil plant material or a reactive extract thereof.

Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

Abstract: The present invention relates to the use and application of a water-soluble or water-dispersible copolymer comprising: a) at least a monomer compound of general formula i: in which R1 is a hydrogen atom, a methyl or ethyl group; R2, R3, R4, R5 and R6, which are identical or different, are linear or branched C1-C6, alkyl, hydroxyalkyl or aminoalkyl groups; m is an integer from 0 to 10; n is an integer from 1 to 6; Z represents a —C(O)O— or —C(O)NH— group or an oxygen atom; A represents a (CH2)p group, p being an integer from 1 to 6; B represents a linear or branched C2-C12, polymethylene chain optionally interrupted by one or more heteroatoms or heterogroups, and optionally substituted by one or more hydroxyl or amino groups; X, which are identical or different, represent counterions; and (b) at least one hydrophilic monomer carrying a functional acidic group which is copolymerizable with (a) and which is capable of being ionized in the application medium; (c) optionally at least one monomer compo

Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.

Abstract: A biodegradable material for use in making items usable in surgery and related fields of medicine. The material comprising a bioabsorbable thermoplastic polymer component and a bioactive filler material. In components made of the material particles of the filler material occur embedded within the surface of the components.

Abstract: A disinfectant wet wipe that contains a germicidal solution and a nonwoven web material is provided. The germicidal solution includes a peracid and peroxide, which can act synergistically together to be efficacious against pathogens when exposed thereto. To stabilize the solution over a period of time (e.g., during storage), a variety of aspects of the wipe are selectively controlled in accordance with the present invention. For example, the nonwoven web material used in the wipe is formed from a synthetic polymer and is relatively hydrophobic in nature. Without intending to be limited by theory, it is believed that such materials possess a lower reduction potential for peroxides/peracids than cellulosic-based materials. In this manner, significant degradation of the peroxide or peracid contained in the germicidal solution is limited. To improve the wettability of the nonwoven web material, one or more surfactants are also employed in the germicidal solution.

Abstract: Provided are structured compositions comprising an anionic surfactant, a betaine, and a branched fatty alcohol, the composition having a Yield Stress from about 1 Pascal (Pa) to about 1500 Pa, as well as methods of making and using such compositions.

Abstract: The present invention provides a pharmaceutical composition, useful for the treatment of diseases characterized by abnormal PTKs activity of erbB family in a mammal, comprising pharmaceutically acceptable salts of N-{4-[3-chloro-4-(3-fluoro-benzyloxy) phenylamino]quinazolin-6-yl}-acrylamide, optionally a pharmaceutically applicable carrier or diluent, and a stabilizer having a dispersing and/or protective effect on the active ingredient. The present invention further provides a pharmaceutical formulation comprising said composition, methods for preparation of said composition and said formulation, as well as use of said composition and said formulation for treating diseases characterized by abnormal PTKs activity of erbB family in a mammal.

Abstract: Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer.

Abstract: The present invention provides a highly tolerable, hydrating lanolin containing foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable composition includes lanolin, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.

Abstract: Method of product evaluation comprising the steps of applying at least one substance to a surface of an artificial substrate to form a substance-coated surface, wherein the substrate surface demonstrates at least one physical property selected from the group consisting of a total surface energy of from about 15 mJ/m2 to about 50 mJ/m2, a polar component of the total surface energy of from about 0 mJ/m2 to about 15 mJ/m2, a zeta-potential at a pH of about 5.0 of from about ?30 mV to about 30 mV, and combinations thereof, and performing at least one analysis of the substance-coated surface.

Abstract: In the preferred embodiment, the invention is a system for creating micropores in the skin for transdermal drug delivery through the micropores and includes: a chemical that dissolves or breaks down superficial layers of skin; a chemical delivery element that holds and delivers controlled volumes of the chemical to skin, creating micropores; and a base that is able to temporarily couple to skin, contains the chemical delivery elements, and may activate the chemical delivery elements to administer the chemical to skin. In the preferred embodiment, the invention is a method for delivering drugs transdermally that includes providing a carrier containing a chemical delivery element with a chemical to break down superficial layers of skin; placing the carrier into contact with skin; activating the chemical delivery element; allowing the chemical to break down superficial layers of skin and creating micropores; and providing a drug to be delivered transdermally through the micropores.

Abstract: The present invention provides an adhesive material to be adhered to the skin etc., which maintains, for a certain time period after adhesion thereof to the skin surface, suitable adhesiveness that does not allow easy peeling or cause irritation to the skin, and which permits, when it is to be peeled off from the skin surface after the lapse of a desired certain time period, easy peeling without causing pain or physical irritation, and an adhesive preparation containing the adhesive material and a percutaneously absorbable drug in the adhesive layer. Specifically, the present invention provides an adhesive material containing a support and an adhesive layer laminated on one surface of the support, wherein the adhesive layer has an apparent viscosity at 30° C. of 0.2×104 to 10×104 Pa·s and comprises two kinds of synthetic rubbers having different flowability.

Abstract: The invention provides an orally disintegrating tablet that has both adequate tablet hardness and rapid disintegrability in the oral cavity, and that undergoes minor hardness reduction and maintains good oral disintegrability even when preserved under moist conditions. In particular, the invention relates to an orally disintegrating tablet containing (a) crystalline cellulose, (b) a calcium hydrogen phosphate compound, (c) a natural starch and (d) a lubricant, wherein the blending ratio to 100 wt % of the disintegrating tablet is (a) 9 to 60 wt %, (b) 16 to 60 wt %, (c) 3 to 40 wt % and (d) 0.01 to 1.8 wt %.

Abstract: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Abstract: Disclosed are microcapsules and processes of microencapsulation of water soluble or water dispersible compounds by reverse-phase microencapsulation and ways to combine them with other oil soluble or oil dispersible compounds in suitable formulations that yield tiny microcapsules and a very homogeneous distribution of particle size. Multiple combinations of these reverse-phase microcapsules are disclosed, including in combination with normal-phase microcapsules in order to create a Capsule Mixed Suspension (CX) where an outer oil phase or, alternatively, a water phase contains microcapsules of two types: those with a core of water and active ingredients dissolved or dispersed therein, and those with a core of oil and active ingredients dissolved or dispersed therein. Water Dispersible Granules (WDG) and Emulsion Concentrates (EC) and Suspension Concentrates (SC) combinations with the reverse phase microcapsules are also successfully performed.

Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.

Abstract: Novel biodegradable polyesteramides derived from optionally functionalized diacids and optionally functionalized diamines or from compounds having both optionally functionalized acid and optionally functionalized amine moieties, their preparation, and absorbable surgical articles fabricated therefrom, such as monofilament and multifilament sutures, films, sheets, plates, clips, staples, pins, screws, stents, stent coatings, packaging materials, and other implantable surgical devices, and the like, are described herein.

Abstract: A nutritional supplement comprising a variety of vitamins and minerals is described. A nutritional supplement comprising between about 1 mg and about 5 mg of vitamin B1, between about 2 mg and about 8 mg of vitamin B2, between about 7 mg and about 30 mg of vitamin B6, between about 10 mcg and about 40 mcg of vitamin B12, between about 1 mg and about 4 mg of folic acid, between about 250 IU and about 900 IU of vitamin D3, between about 100 mg and about 400 mg of vitamin C, between about 20 IU and about 90 IUs of vitamin E, between about 0.5 mg and about 4 mg of copper, between about 20 mg and about 80 mg of zinc, between about 10 mg and about 70 mg of iron, and between about 100 mg and about 800 mg of omega-3 fatty acids is disclosed.